Investigational new drugs for the treatment of acute coronary syndrome

Bibliography

• Centres for Disease Control and Prevention. Deaths: Final Data for 2013. Natl Vital Stat Rep 2013;64:2
   Google Scholar
• World Health Organisation. The 10 leading causes of death in the world, 2000 and 2012. Fact sheet N°310. Updated May 2014
   Google Scholar
• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American heart association. Circulation 2013;127(1):e6–e245
   PubMed Web of Science ®Google Scholar
• Department of Economic and Social Affairs Population Division, United Nations World Population Aging: 1950 - 2050 Sales No. E.02.XIII.3 ISBN 92-1-051092-5
   Google Scholar
• Smolina K, Wright FL, Rayner M, et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes 2012;5:532-40
   PubMed Web of Science ®Google Scholar
• Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001;88(8A):10K-5K
   PubMed Web of Science ®Google Scholar
• Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014;114:1867-79
   PubMed Web of Science ®Google Scholar
• Falk E, Nakano M, Bentzon JF, et al. Update on acute coronary syndromes: the pathologists view. Eur Heart J 2013;34:719-28
   PubMed Web of Science ®Google Scholar
• Davi G, Patrono C. Platelet activation and atherothrombosis. N Eng J Med 2007;357:2482-94
   PubMed Web of Science ®Google Scholar
• Meuwissen M, Van der Wal AC, Siebes M, et al. Role of plaque inflammation in acute and recurrent coronary syndromes. Neth Heart J 2004;12(3):106-8
   PubMedGoogle Scholar
• Boyle JJ. Association of coronary plaque rupture and atherosclerotic inflammation. J Pathol 1997;181(1):93-9
   PubMed Web of Science ®Google Scholar
• Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32:2999-3054
   PubMed Web of Science ®Google Scholar
• Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes. Circulation 2014;130:e344-426
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 2013;61(4):e78-e140
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361(24):2330-41
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischaemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163:182-90
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382(9909):1981-92
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA news release: FDA approves new antiplatelet drug used during heart procedure. 2015
   Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012;307(3):265-74
   PubMed Web of Science ®Google Scholar
• Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv 2012;5(3):336-46
   PubMed Web of Science ®Google Scholar
• Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. gradient of benefit related to the revascularisation strategy. Eur Heart J 2002;23:1441-8
   PubMed Web of Science ®Google Scholar
• US Patent Office. Transdermal pharmaceutical preparation and administration of tirofiban. Publication Number US 0029447 A1; 2012
   Google Scholar
• Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102:449-61
   PubMed Web of Science ®Google Scholar
• Ungerer M, Rosport K, Bültmann A, et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011;123:1891-9
   PubMed Web of Science ®Google Scholar
• AdvanceCor GmbH. Revacept in symptomatic carotid stenosis (Revacept/CS/02). Available from: https://clinicaltrials.gov/ct2/show/NCT01645306
   Google Scholar
• Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007;100:1261-75
   PubMed Web of Science ®Google Scholar
• Baker NC, Lipinski MJ, Lhermusier T, Waksman R. Overview of the 2014 food and drug administration cardiovascular and renal drugs advisory committee meeting about vorapaxar. Circulation 2014;130(15):1287-94
   PubMed Web of Science ®Google Scholar
• Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012;366(1):20-33
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13
   PubMed Web of Science ®Google Scholar
• Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 2015;131(12):1047-53
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes. Circulation 2011;123:1843-53
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Flather MD, O’Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation 2011;123(17):1854-63
   PubMed Web of Science ®Google Scholar
• Il Dong Pharmaceutical Co Ltd. Randomized, double-blind, placebo-controlled, dose-escalation, repeated and single oral dosing phase I study to assess the pharmacokinetics, pharmacodynamics and safety of APD791 (Temanogrel) co-administered with aspirin and clopidogrel. ClinicalTrials.gov Identifier: NCT02419820
   Google Scholar
• Capra V, Back M, Angiolillio DJ, et al. Impact of vascular thromboxane prostanoid receptor activationon homeostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost 2014;12:126-37
   PubMed Web of Science ®Google Scholar
• Hong TT, Huang J, Driscoll E, et al. Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol 2006;48(5):239-48
   PubMed Web of Science ®Google Scholar
• Bousser MG, Amarenco P, Chamorro A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377(9782):2013-22
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143(4):241-50
   PubMed Web of Science ®Google Scholar
• Andreotti F, Testa L, Biondi-Zoccai GG, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006;27(5):519-26
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32(22):2781-9
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19
   PubMed Web of Science ®Google Scholar
• Food and Drugs Administration. FDA briefing document for the cardiovascular and renal drugs advisory committee (CRDAC) for Xarelto® (Rivaroxaban) oral tablets. 2012
   Google Scholar
• European Medicines Agency. Summary of opinion: Rivaroxaban. 2013 EMA/CHMP/183242/2013
   Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
   PubMed Web of Science ®Google Scholar
• APPRAISE Steering Committee and Investigators. Alexander JH, Becker RC, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation 2009;119(22):2877-85
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365(8):699-708
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin–antithrombin III but is susceptible to inactivation by antithrombin III–independent inhibitors. J Clin Invest 1990;86:385-91
   PubMed Web of Science ®Google Scholar
• Hirsh J, Raschke R, Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-75S
   PubMed Web of Science ®Google Scholar
• Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333(12):764-9
   PubMed Web of Science ®Google Scholar
• Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142(6):952-9
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289(7):853-63
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30
   PubMed Web of Science ®Google Scholar
• Stone GW, Clayton T, Deliargyris EN, et al. The HORIZONS-AMI trial (harmonizing outcomes with revascularization and stents in acute myocardial infarction). J Am Coll Cardiol 2014;63(1):15-20
   PubMed Web of Science ®Google Scholar
• Steg PG, Van ’t Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-17
   PubMed Web of Science ®Google Scholar
• Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58
   PubMed Web of Science ®Google Scholar
• Valgimigli M. for the MATRIX group. Bivalirudin infusion compared to unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: results from the minimizing adverse haemorrhagic events by transradial access site and systemic implementation of angiox (matrix) anti-thrombin program late-breaking clinical trials V: TCT@ACC-i2 Interventional cardiology. Presented at American College of Cardiology Scientific Sessions; 14 – 16 March 2015; San Diego
   Google Scholar
• Piccolo R, De Biase C, D’Anna C, et al. Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention. A meta-analysis of randomised clinical trials. Thromb Haemost 2015;113(5):1010-20
   PubMed Web of Science ®Google Scholar
• Cavender MA, Sabatinex MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014;384(9943):599-606
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Cohen MG, Mehran R, et al. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. Am Heart J 2011;161(2):261-268e1-2
   PubMed Web of Science ®Google Scholar
• Regado Biosciences, Inc. A Study to determine the efficacy and safety of REG1 compared to bivalirudin in patients undergoing PCI. ClinicalTrials.gov Identifier: NCT01848106
   Google Scholar
• Regado Biosciences. Regado biosciences permanently halts REGULATE-PCI clinical trial [press release]. 2014
   Google Scholar
• Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008;10(3):218-27
   PubMedGoogle Scholar
• Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 2012;39(7):1458-64
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61(4):404-10
   PubMed Web of Science ®Google Scholar
• Papoutsidakis N, Sianos G, Goudevenos J, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Tardif JC, L’Allier PL, Grégoire J, et al. A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010;3(6):543-8
   PubMed Web of Science ®Google Scholar
• Newby LK, Marber MS, Melloni C, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 2014;384(9949):1187-95
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. A Phase 3 clinical outcomes study to compare the incidence of major adverse cardiovascular events in subjects presenting with acute coronary syndrome treated with losmapimod compared to placebo (LATITUDE-TIMI 60). ClinicalTrials.gov Identifier: NCT02145468
   Google Scholar
• The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375(9725):1536-44
   PubMed Web of Science ®Google Scholar
• Serruys PW, García-García HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118(9):1172-82
   PubMed Web of Science ®Google Scholar
• The STABILITY Investigators. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 2014;312(10):1006-15
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014;311(3):252-62
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-32
   PubMed Web of Science ®Google Scholar
• Roubille F, Busseuil D, Shi Y, et al. The interleukin-1beta modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis 2014;236(2):277-85
   PubMed Web of Science ®Google Scholar
• EU Clinical Trials Register. Evaluation of the subcutaneous administration of 30 mg of S78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S78989 versus placebo on the reduction of arterial wall inflammation in patients with marked atherosclerotic plaque inflammation. EudraCT Number: 2012-002677-53
   Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009(1):CD005121
   Google Scholar
• Morton AC, Foley C, Rothman A, et al. Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study). Heart 2011;97:A13
   Web of Science ®Google Scholar
• Sibley CH, Chioato A, Felix S, et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis 2015;74(9):1714-19
   PubMed Web of Science ®Google Scholar
• Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on IL-6, fibrinogen, and hsCRP: A Randomised placebo-controlled trial. J Am Coll Cardiol 2012;59(13s1):E1539
   Google Scholar
• Novartis Pharmaceuticals. Cardiovascular risk reduction study (reduction in recurrent major CV disease events) (CANTOS). ClinicalTrials.gov Identifier: NCT01327846; 2011 [Last accessed 19 May 2015]
   Google Scholar
• Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 2000;95(2):75-83
   PubMed Web of Science ®Google Scholar
• Rizzon P, Biasco G, Di Biase M, et al. High doses of L-carnitine in acute myocardial infarction: metabolic and antiarrhythmic effects. Eur Heart J 1989;10(6):502-8
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Lavie CJ, Fares H, et al. L-Carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc 2013;88(6):544-51
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Mengjun W, Zhang K, et al. Long-term therapy with Bendavia (MTP-131), a novel mitochondria-targatting peptide, increases myocardial ATP synthesis and improves left ventricular systolic function in dogs with chronic heart failure. J Am Coll Cardiol 2013;61:10S
   Web of Science ®Google Scholar
• Chakrabarti AK, Feeney K, Abueg C, et al. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J 2013;165(4):509-514.e7
   PubMed Web of Science ®Google Scholar
• Michael Gibson C, et al. The EMBRACE STEMI Study: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia™ on Reperfusion Injury in Patients Treated with Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction (EMBRACE STEMI) Late-Breaking Clinical Trials V: TCT@ACC-i2 Interventional Cardiology. Presented at American College of Cardiology Scientific Sessions; 14 – 16 March 2015; San Diego
   Google Scholar
• Ganong WF. Review of medical physiology 22nd edition Chapter 27. Mcgraw-hill 2005. p. 530
   Google Scholar
• Mott JL, Zhang D, Freeman JC, et al. Cardiac disease due to random mitochondrial DNA mutations is prevented by cyclosporin A. Biochem Biophys Res Commun 2004;319(4):1210-15
   PubMed Web of Science ®Google Scholar
• Youn TJ, Piao H, Kwon JS, et al. Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction. Eur J Heart Fail 2002;4(6):713-18
   PubMed Web of Science ®Google Scholar
• Elrod JW, Wong R, Mishra S, et al. Cyclophilin D controls mitochondrial pore-dependent Ca2+ exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest 2010;120(10):3680-7
   PubMed Web of Science ®Google Scholar
• Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-81
   PubMed Web of Science ®Google Scholar
• Mewton N, Croisille P, Gahide G, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010;55:1200-5
   PubMed Web of Science ®Google Scholar
• Nakamura R, Takahashi A, Yamada T, et al. Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention. Circ J 2009;73(10):1920-6
   PubMed Web of Science ®Google Scholar
• Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. PNAS 2003;100(20):11612-17
   PubMed Web of Science ®Google Scholar
• Binbrek AS, Rao NS, Khaja NA, et al. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. JAMA 2009;104(8):1035-40
   Web of Science ®Google Scholar
• Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010;3(5):408-13
   PubMed Web of Science ®Google Scholar
• Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011;305(18):1863-72
   PubMed Web of Science ®Google Scholar
• Koh GY, Klug MG, Soonpaa MH, et al. Differentiation and long-term survival of C2C12 myoblast graft in heart. J Clin Invest 1993;92:1548-54
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5
   PubMed Web of Science ®Google Scholar
• Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 2005;102:11474-9
   PubMed Web of Science ®Google Scholar
• Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodelling and improves cardiac function. Nat Med 2001;7:430-6
   PubMed Web of Science ®Google Scholar
• Schächinger V, Erbs S, Elsässer A, et al. Improved clinical outcome after intracoronary administration of bone-marrow- derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27(23):2775-83
   PubMed Web of Science ®Google Scholar
• Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012;2:CD006536
   PubMedGoogle Scholar
• Queen Mary University of London BAMI. The Effect of intracoronary reinfusion of bone marrow-derived mononuclear cells(BM-MNC) on all cause mortality in acute myocardial infarction. ClinicalTrials.gov Identifier: NCT01569178.
   Google Scholar
• Johnson TW, Marsden D, Mumford A, et al. Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper. BMC Cardiovasc Disord 2014;14:44
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, Palmer K, Pakyz RE, et al. Implementation of pharmacogenetics: the University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet 2014;166C(1):76-84
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357(20):2001-15
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar